Myers Scott Dunseth

Director Myers Scott Dunseth buys 3,800 shares of DVAX at $10.82; stock now -27.8% from 52-week high.

Director Myers Scott Dunseth purchased 3,800 shares at $10.82 on 2025-08-22, increasing his holdings to 35,004 shares. The current price of $10.39 is -27.8% from the 52-week high of $14.40, indicating the purchase occurred near recent lows. However, Dunseth's cross-ticker track record across his open-market activity shows 2 prior buys with an average 90-day return of -19.2% and a 90-day win rate of 0.00%, suggesting this insider's prior buy decisions have not generated positive subsequent returns. Despite the company's solid near-term fundamentals—revenue of $95,442,000.00 with net income of $18,721,000.00 and annual revenue growth of +19.4%—the elevated P/E of 49.48 and the insider's consistent negative post-buy returns warrant investor caution.

Director Myers Scott Dunseth buys 21,000 ZNTL shares at $1.40; stock down 88.7% from 52-week high, company posted $-40.2M loss

Director Myers Scott Dunseth purchased 21,000 shares of Zentalis Pharmaceuticals at $1.40 on 2025-04-30, increasing his holdings to 281,192 shares, during a period when the stock trades at $1.42 and has declined 88.7% from its 52-week high of $12.54. The company is unprofitable with a $-40,158,000 net loss in its most recent fiscal year and zero revenue in the latest quarter, indicating an early-stage biotech profile with significant operational losses. Dunseth's historical cross-ticker buy performance shows an average 90-day return of -19.2% with a 0.00% win rate, establishing a pattern of unfavorable subsequent price action following his purchases. This buy occurs while the stock is already significantly depressed in price; investors should monitor whether this transaction reflects access to non-public information regarding clinical progress or financing, or whether it represents a continuation of Dunseth's historical pattern of purchases preceding further declines.